The city of Newport Beach, California, currently has 4 active clinical trials seeking participants for Pulmonary Fibrosis research studies.
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Recruiting
Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: NewportNativeMD, Inc., Newport Beach, California
Conditions: Progressive Pulmonary Fibrosis, Interstitial Lung Disease
A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting
Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: GSK Investigational Site, Newport Beach, California
Conditions: Idiopathic Pulmonary Fibrosis
Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients with IPF
Recruiting
This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks. Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers). An interim analysis will... Read More
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
03/04/2025
Locations: Newport Native MD, Inc., Newport Beach, California
Conditions: Idiopathic Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants with Progressive Pulmonary Fibrosis
Recruiting
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/10/2025
Locations: Newport Native MD, Inc., Newport Beach, California
Conditions: Progressive Pulmonary Fibrosis